Clinical Trial Update: MNPR-101-DFO*-89Zr Expanded Access Program (EAP) for Patients With Solid Tumor Cancer

View source ↗

Summary

An Expanded Access Program update for MNPR-101-DFO*-89Zr in patients with solid tumors, sponsored by Monopar Therapeutics; the program is currently available.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Cancer
• Solid Tumors

Drugs mentioned

• MNPR-101-DFO*-89Zr

Snippet

Sponsor: Monopar Therapeutics | Conditions: Cancer, Solid Tumor | Status: AVAILABLE